JP2023538369A - 抗ｃｄ７３抗体とその使用 - Google Patents

抗ｃｄ７３抗体とその使用 Download PDF

Info

Publication number
JP2023538369A
JP2023538369A JP2023511960A JP2023511960A JP2023538369A JP 2023538369 A JP2023538369 A JP 2023538369A JP 2023511960 A JP2023511960 A JP 2023511960A JP 2023511960 A JP2023511960 A JP 2023511960A JP 2023538369 A JP2023538369 A JP 2023538369A
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023511960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538369A5 (https=
JPWO2022037531A5 (https=
Inventor
チョンミン ワン
シアオピン チン
パイヨン リー
ユイ シア
Original Assignee
アケソ バイオファーマ カンパニー，リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アケソ バイオファーマ カンパニー，リミティド filed Critical アケソ バイオファーマ カンパニー，リミティド
Publication of JP2023538369A publication Critical patent/JP2023538369A/ja
Publication of JP2023538369A5 publication Critical patent/JP2023538369A5/ja
Publication of JPWO2022037531A5 publication Critical patent/JPWO2022037531A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023511960A 2020-08-17 2021-08-16 抗ｃｄ７３抗体とその使用 Pending JP2023538369A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010828886 2020-08-17
CN202010828886.4 2020-08-17
CN202011152518.9 2020-10-23
CN202011152518 2020-10-23
PCT/CN2021/112771 WO2022037531A1 (zh) 2020-08-17 2021-08-16 抗cd73的抗体及其用途

Publications (3)

Publication Number Publication Date
JP2023538369A true JP2023538369A (ja) 2023-09-07
JP2023538369A5 JP2023538369A5 (https=) 2024-08-26
JPWO2022037531A5 JPWO2022037531A5 (https=) 2024-08-26

Family

ID=80283259

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511960A Pending JP2023538369A (ja) 2020-08-17 2021-08-16 抗ｃｄ７３抗体とその使用

Country Status (7)

Country Link
US (1) US20240218074A1 (https=)
EP (1) EP4197555A4 (https=)
JP (1) JP2023538369A (https=)
CN (1) CN114075289B (https=)
AU (1) AU2021326889A1 (https=)
CA (1) CA3191745A1 (https=)
WO (1) WO2022037531A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021087463A1 (en) * 2019-11-01 2021-05-06 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-cd73 antibodies and uses thereof
WO2023206242A1 (zh) * 2022-04-28 2023-11-02 江苏中新医药有限公司 无钩状效应的抗人cd73单克隆抗体
CN117304316A (zh) * 2022-06-22 2023-12-29 复旦大学 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
JP2017534648A (ja) * 2014-11-11 2017-11-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2017537620A (ja) * 2014-11-21 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
JP2018501197A (ja) * 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
JP2018502151A (ja) * 2015-01-15 2018-01-25 欧詩漫生物股▲ふん▼有限公司Ｏｓｍ Ｂｉｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 真珠タンパクの調製方法、該方法で調製される水溶性真珠タンパク及び酸可溶性真珠タンパク
WO2018110555A1 (ja) * 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
WO2018215535A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
JP2019503709A (ja) * 2015-12-09 2019-02-14 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
JP2019514844A (ja) * 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
JP2020515508A (ja) * 2017-01-24 2020-05-28 アイ−エムエービー バイオファーマ ユーエス リミテッド 抗ｃｄ７３抗体およびその使用
JP2020530263A (ja) * 2017-06-22 2020-10-22 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
JP2020186244A (ja) * 2014-10-10 2020-11-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ７３遮断
JP2021516057A (ja) * 2018-03-09 2021-07-01 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ７３抗体及びその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
CN110240654A (zh) * 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
TWI823906B (zh) * 2018-03-09 2023-12-01 美商艾吉納斯公司 抗-cd73 抗體及其使用方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020186244A (ja) * 2014-10-10 2020-11-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． Ｃｄ７３遮断
JP2018501197A (ja) * 2014-11-10 2018-01-18 メディミューン リミテッド Ｃｄ７３特異的結合分子及びその使用
JP2017534648A (ja) * 2014-11-11 2017-11-24 メディミューン リミテッド 抗ｃｄ７３抗体とａ２ａ受容体阻害薬とを含む併用治療薬及びその使用
JP2017537620A (ja) * 2014-11-21 2017-12-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
JP2018502151A (ja) * 2015-01-15 2018-01-25 欧詩漫生物股▲ふん▼有限公司Ｏｓｍ Ｂｉｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 真珠タンパクの調製方法、該方法で調製される水溶性真珠タンパク及び酸可溶性真珠タンパク
WO2017064043A1 (en) * 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
JP2019503709A (ja) * 2015-12-09 2019-02-14 コーバス・ファーマシューティカルズ・インコーポレイテッド ヒト化抗ｃｄ７３抗体
JP2019514844A (ja) * 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
WO2018110555A1 (ja) * 2016-12-13 2018-06-21 アステラス製薬株式会社 抗ヒトｃｄ７３抗体
JP2020515508A (ja) * 2017-01-24 2020-05-28 アイ−エムエービー バイオファーマ ユーエス リミテッド 抗ｃｄ７３抗体およびその使用
WO2018215535A1 (en) * 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
JP2020530263A (ja) * 2017-06-22 2020-10-22 ノバルティス アーゲー Ｃｄ７３に対する抗体分子及びその使用
JP2021516057A (ja) * 2018-03-09 2021-07-01 フェインズ セラピューティクス，インコーポレーテッド 抗ｃｄ７３抗体及びその使用

Also Published As

Publication number Publication date
CA3191745A1 (en) 2022-02-24
AU2021326889A1 (en) 2023-03-23
EP4197555A1 (en) 2023-06-21
US20240218074A1 (en) 2024-07-04
CN114075289A (zh) 2022-02-22
CN114075289B (zh) 2024-07-02
WO2022037531A1 (zh) 2022-02-24
EP4197555A4 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
JP2023538369A (ja) 抗ｃｄ７３抗体とその使用
TWI728250B (zh) 靶向hiv gp120及cd3之多特異性抗體
ES3001154T3 (es) Anticuerpo monoclonal anti-PD1, composición farmacéutica del mismo y uso del mismo
US12595302B2 (en) CLDN18.2 binding molecule
CN106967172B (zh) 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
US20210388105A1 (en) Novel anti-cd39 antibodies
KR102602329B1 (ko) Cd3에 특이적인 항체 및 이의 용도
CN114380915B (zh) 抗cd73的抗体及其用途
US20190270818A1 (en) Pd-1 agonist antibodies and uses thereof
CN111526888A (zh) 抗tigit抗体及其作为治疗和诊断的用途
TW200927760A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
JP2018522568A (ja) ヒト化抗ｃｃｒ７受容体抗体
KR20230125774A (ko) 항-cd73 항체 및 이의 용도
TW201916890A (zh) 抗ｐｄ－１抗體和抗ｌａｇ－３抗體聯合在製備治療腫瘤的藥物中的用途
CN114106182B (zh) 抗tigit的抗体及其用途
US20240182562A1 (en) Cldn18.2 antigen-binding protein and use thereof
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
TW202305000A (zh) 表現抗ror1/抗cd3雙特異性抗體之溶瘤病毒
US20240270827A1 (en) Compositions and methods for anti-virus chimeric antigen receptor
CN117624352A (zh) 抗Tmem176b抗体、药物组合物及用途
CN116606373A (zh) 新型冠状病毒中和抗体及其用途
CN117098782A (zh) 靶向cldn18.2的抗原结合蛋白及其用途
TW202241955A (zh) Ｇａｒｐ蛋白抗體及其應用
HK40089235A (en) Anti-cd73 antibody and use thereof
RU2780537C2 (ru) Cd3-специфические антитела и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240815

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260331